Nanotechnology - Nanoparticles; Researchers from Monash Institute of Pharmaceutical Sciences Report Findings in Nanoparticles (The impact of size and charge on the pulmonary pharmacokinetics and immunological response of the lungs to PLGA nanoparticles after intratracheal ...)

Press/Media: Article/Feature

Period30 Sep 2020

Media coverage

1

Media coverage

  • TitleNanotechnology - Nanoparticles; Researchers from Monash Institute of Pharmaceutical Sciences Report Findings in Nanoparticles (The impact of size and charge on the pulmonary pharmacokinetics and immunological response of the lungs to PLGA nanoparticles after intratracheal ...)
    Degree of recognitionInternational
    Media name/outletBiotech Week, Atlanta
    Media typePrint
    CountryUnited States of America
    Date30/09/20
    Description 2020 SEP 30 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- New research on Nanotechnology - Nanoparticles is the subject of a report. According to news reporting out of Parkville, Australia, by NewsRx editors, research stated, "Polylactide-co-glycolide (PLGA) nanoparticles are one of the most commonly explored biodegradable polymeric drug carriers for inhaled delivery. Despite their advantages as inhalable nanomedicine scaffolds, we still lack a complete understanding of the kinetics and major pathways by which these materials are cleared from the lungs."

    Our news journalists obtained a quote from the research from the Monash Institute of Pharmaceutical Sciences, "This information is important to evaluate their safety over prolonged use and enable successful clinical translation. This study aimed to determine how the size and charge of H-labeled PLGA nanoparticles affect the kinetics and mechanisms by which they are cleared from the lungs and their safety in the lungs. The results showed that lung clearance kinetics and retention patterns were more significantly defined by particle size, whereas lung clearance pathways were largely influenced by particle charge."

    According to the news editors, the research concluded: "Each of the nanoparticles caused transient inflammatory changes in the lungs after a single dose that reflected lung retention times."

    For more information on this research see: The impact of size and charge on the pulmonary pharmacokinetics and immunological response of the lungs to PLGA nanoparticles after intratracheal administration to rats. Nanomedicine, 2020;():102291. (Elsevier - www.elsevier.com; Nanomedicine - www.journals.elsevier.com/nanomedicine-nanotechnology-biology-and-medicine/)

    Our news journalists report that additional information may be obtained by contacting Colin W. Pouton, Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia. Additional authors for this research include Shadabul Haque, Michelle P. McIntosh, David B. Ascher, David W. Keizer, Michael Whittaker and Lisa M. Kaminskas. and can be your direct source for a journal article and its citation.

    Keywords for this news article include: Parkville, Pharmacology, Nanoparticles, Nanotechnology, Pharmacokinetics, Health and Medicine, Emerging Technologies, Australia and New Zealand.

    Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2020, NewsRx LLC

    The citation for this news report is: NewsRx. Researchers from Monash Institute of Pharmaceutical Sciences Report Findings in Nanoparticles (The impact of size and charge on the pulmonary pharmacokinetics and immunological response of the lungs to PLGA nanoparticles after intratracheal ...). Biotech Week. September 30, 2020; p 1162.
    URLhttps://search.proquest.com/docview/2447293761?accountid=12528
    PersonsShadab Haque